Evusheld预防性用药对疫苗无应答免疫功能低下患者SARS-CoV-2奥密克戎变异株感染有效性的「真实世界」观察性研究(REALISE)
该观察性研究纳入2022年3月至9月期间免疫功能低下患者,比较接受Evusheld暴露前预防组(43例,抗刺突IgG抗体<260 BAU/ml)与未暴露组(45例)在意大利奥密克戎流行期间的症状性感染率。Evusheld组症状性感染率为23.3%,未暴露组为42.2%。Evusheld组抗体水平在入组180天后仍高于基线阈值。作者认为Evusheld似乎可降低免疫功能低下患者的症状性感染率,但需进一步数据确定该预防措施是否具有更持久的效果。
要点
- Evusheld组症状性感染率为23.3%,未暴露组为42.2%。
- 感染多发生于男性患者。
- 两组感染持续时间无差异。
核心结论
- Evusheld似乎可降低免疫功能低下患者的症状性感染率。
- 需要进一步数据来确定该预防措施是否可能具有更持久的效果。
研究设计与样本
- 观察性研究,比较暴露组(Evusheld组)与未暴露组。
- Evusheld组于2022年3月至9月入组免疫功能低下患者,所有患者在给药前抗刺突IgG抗体水平<260 BAU/ml。
- 未暴露组在入组时进行血清学检测,6个月后完成问卷。
- Evusheld组43例接受Evusheld暴露前预防,未暴露组45例未接受Evusheld。
- Evusheld组中位年龄59.0岁,未暴露组中位年龄63.0岁。
主要发现
- 在意大利奥密克戎流行期间,Evusheld组23.3%的受试者出现症状性感染,未暴露组为42.2%。
- 感染多数发生于男性患者。
- 两组感染持续时间无差异。
- Evusheld组入组180天后抗体水平仍高于基线阈值。
局限性
- 需要进一步数据来确定该预防措施是否可能具有更持久的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infection by SARS-CoV2 has become a challenge, especially for immunocompromised patients who show a weaker humoral response to COVID-19 vaccine. Tixagevimab+cilgavimab (Evusheld) is a combination of human monoclonal antibodies that can be used for pre-exposure prophylaxis to prevent infection or disease by SARS-CoV2. OBJECTIVES: Our study aimed to investigate the effectiveness of Evusheld by comparing an Exposed and an Unexposed group. STUDY DESIGN: Immunocompromised patients were enrolled in the Evusheld Group between March and September 2022. All patients had anti-spike IgG antibody levels <260 BAU/ml before administration of Evusheld. Blood samples for serological evaluations were collected, and anti-Spike antibodies were tested. For the Unexposed Group, a serologic test was performed at enrollment and a questionnaire was performed after 6 months. RESULTS: 43 patients received Evusheld pre-exposure prophylaxis and 45 patients not receiving Evusheld were enrolled in the Unexposed group. The median age was 59.0 years in the Evusheld group, and 63.0 in the unexposed group. In the Evusheld group, during the Omicron wave in Italy, 23.3% of subjects developed symptomatic infection compared to 42.2% in the unexposed group. A majority of infections was seen in male respect to female patients. No difference in length of infection between the groups was seen. Antibody level remained higher than the basal threshold at 180 days from enrollment. CONCLUSIONS: Evusheld seems to reduce the rate of symptomatic infection in immunocompromised patients. Further data are required to determine whether this prophylaxis may have a longer-lasting effect over time.
引用
- Esposito GL, Fassio F, Girardi D, et al. "REAl LIfe" observational study on the effectiveness of Evusheld prophylaxis against SARS-CoV-2 omicron variants in vaccine non-responder immunocompromised patients (REALISE). Vaccine. 2024. PMID: 39154513. doi:10.1016/j.vaccine.2024.126208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。